ZIDOLAM (Lamivudine & Zidovudine)

ZIDOLAM (Lamivudine & Zidovudine) is a combined antiretroviral drug used for the treatment of HIV infection in children over 12 years old (over 14 kg) and adults who have progressive immunodeficiency. Its action is based on high inhibition of HIV-1 and HIV-2 due to lamivudine and zidovudine, two main active ingredients. These constituents of Duovir are able to reduce the number of HIV cells in the body and increase the number of CD4 + cells. Due to this, the use of Duovir, as well as therapy, which includes treatment with lamivudine and zidovudine along with other drugs, significantly reduces the risk of developing the disease and the death of the patient. With regard to inhibition of HIV cell replication in the body, lamivudine and zidovudine play a common complementary role with the former acting as a synergist for the latter. Both active ingredients of the drug are almost completely absorbed from the gastrointestinal tract, subsequently being metabolized by intracellular kinases to triphosphate (TF). The main antiviral activity of Duovir is due to the inclusion of its monophosphate constituents in the DNA strand affected by the virus, as a result of which it breaks.

Duovir therapy should only be performed under the supervision of an experienced physician experienced in treating HIV infections, as serious side effects may develop.